Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

PETA pumps millions into scientific research in bid to spare lab animals

A SHLAND, Mass. — The foreskins, eyes, lungs, and bits of breasts arrive at the old clock factory in rush deliveries. These surgical leftovers, which patients have donated to science, provide some of the building blocks to grow model human tissues in lab dishe

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

A SHLAND, Mass. — The foreskins, eyes, lungs, and bits of breasts arrive at the old clock factory in rush deliveries. These surgical leftovers, which patients have donated to science, provide some of the building blocks to grow model human tissues in lab dishes. But creating new kinds of lab-grown tissues is expensive, so the project gets a little financial help from a surprising source: People for the Ethical Treatment of Animals. The global animal rights network is both reviled and feared by many scientists, who worry their labs — or their homes — will be the next target for protests and lurid street theater . Yet PETA also funds a science organization that expects to spend more than $200,000 this year supporting academic researchers and biotech companies working on alternatives to using animals in science and medicine. All told, PETA groups around the world have contributed $4 million to science since 1998. Funding science is still hardly PETA’s top priority: The $4 million is practically nothing compared to the $47 million that the American affiliate alone spent on its operations in 2014. But the projects it does support provide a window into the weird world of recreating the human body in the lab. There’s TraumaMan , a dummy whose layers of synthetic skin and fat look, feel, cut, bleed, and suture just like human flesh. Since 2013, PETA has helped purchase a small fleet of these guys — worth over $2 million — to distribute among medical training programs in the developing world so that doctors-to-be can practice their moves on TraumaMen instead of pigs and goats. The animal rights group has also backed the development of computer models that predict how different shapes of molecules will affect our bodies. It has supported academics in Europe who are trying figure out if it’s safe to inhale tiny particles commonly used in manufacturing electronics. “I say bravo to any organization, even an animal rights organization, that funds alternatives” to animal testing. J. David Jentsch, neuroscientist And then there are the model human tissues, including a model of the sacs in our lungs, made with the cells isolated from surgical leftovers. They’re being developed by MatTek, a small biotech company headquartered in a repurposed clock factory in Ashland, Mass. PETA has paid an outside lab to work on the complicated, and expensive, process of validating that MatTek’s lab-grown skin performs as well as animal models in biomedical research. That validation is needed to secure regulatory approval for drug companies to use the MatTek tissue in preclinical trials. “We can’t produce an endless stream of tissue for a validation study without getting compensation for it,” said Mitch Klausner, MatTek’s vice president of scientific affairs. PETA says it’s doing this work not just to save animals, but also to help humans. Mice and rabbits don’t react to chemicals and drugs the way we do, so it’s important to find alternative ways of testing these substances, said Jessica Sandler, director of the PETA International Science Consortium. “PETA is known for caring about the animals,” she said. “But this is also an issue of good science.” The statement has some backing within the scientific community. “Ninety-five percent of drugs fail when they get into human trials, either because they were toxic and it wasn’t predicted in the animal tests, or they have no efficacy despite the fact that the animal test said it worked,” said Dr. Thomas Hartung, director of the Johns Hopkins Center for Alternatives to Animal Testing. But many scientists aren’t so sure. They support the goal of using fewer animals in research and testing. They just don’t trust PETA. To them, trying to end all animal research is too extreme. Without animal testing on experimental drugs, many diseases that are now easily managed with medication would still be killing hordes of people, said J. David Jentsch, a neuroscientist at State University of New York at Binghamton, and founder of the pro-animal research group Pro-Test for Science. He called some of PETA’s tactics dangerous, citing the group’s campaign in October, when it accused two researchers at the National Institutes of Health of animal abuse — and sent a letter with the scientists’ names and home addresses to hundreds of residents in the Washington, D.C. area. The group has targeted both academic researchers and biotech companies in the past. Juan Carlos Marvizon, a neuroscientist at the University of California, Los Angeles, and a member of the pro-animal research group Speaking of Research, wonders whether scientists should believe PETA’s claims — or trust the research the group supports. “PETA is full of ideologues, and we are going to worry it’s biased in some way,” he said. But scientists who have received PETA grants aren’t concerned about being funded by an activist organization. “I’m not influenced by them. I’m still free in research, and can communicate all findings,” said Barbara Rothen-Rutishauser, a professor at the University of Fribourg in Switzerland. In September, her research team received a $140,000 grant from the PETA International Science Consortium to use MatTek tissues to study how inhaling small particles might damage people’s lungs. The animal rights organization isn’t funding every step of the long process to develop alternative models for testing drugs. “ These methods take many years — decades — and many multimillions of dollars to create, and then millions of dollars more to get them validated,” said Sandler. But PETA will step in if an alternative test needs “a final push in order for it to be approved internationally,” she said.

In a street theater performance in April 2015 in New Delhi, PETA activists demonstrate how animals are abused and killed in laboratories. Prakash Singh/AFP/Getty Images

Even PETA’s staunchest opponents hope that this is a step in the right direction. Jentsch, for example, has good reason to be wary of animal rights activists. His car was firebombed outside of his house in 2009, when he was a professor at University of California, Los Angeles. A year later, he received a package of bloody razor blades, with a letter that imagined his murder in graphic detail. The extremist group Animal Liberation Front claimed responsibility for the bombing. Jentsch says he’s disgusted that PETA continues to release scientists’ home addresses, given that such violence has been committed in the past. Yet he grudgingly supports the group’s work to fund research. “I say bravo to any organization, even an animal rights organization, that funds alternatives” to animal testing. “But they’re the followers,” he said. “Scientists need to be given the credit for developing the vast majority of alternatives that exist.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What Comes Next

With data expected in the fourth quarter of 2026, we are prioritizing histology alongside patient-reported outcomes using the Celiac Disease Symptom Diary, one of only two instruments developed in line with U.S. Food and Drug Administration (FDA) guidance, to capture changes in symptoms such as abdominal pain and nausea. Ultimately, the broader aim is to give gastroenterologists and patients a therapeutic option for a disease that has long been managed without one. The future of drug development will not be defined by statistical significance alone, but by whether new therapies also improve the daily burden of living with celiac disease. “The first therapy to cross the line could change the field,” Geller concluded. “It would help establish celiac as a serious medical condition with options beyond a restrictive diet and open the door for what comes next.” Dr. Paul Lizzul is chief medical officer at First Tracks Biotherapeutics, a clinical ‑ stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. Marilyn Geller serves as an advisor to First Tracks Bio. Footnotes Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev . 2014;260(1):221-234. https://doi.org/10.1111/imr.12191. Yokoyama S, Watanabe N, Sato N, et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci U S A . 2009;106(37):15849-15854. https://doi/full/10.1073/pnas.0908834106. Anthony S, Schluns KS. Emerging roles for IL-15 in the activation and function of T-cells during immune stimulation. Research and Reports in Biology . 2015;6:25-37. https://doi.org/10.2147/RRB.S57685.

Source: www.biopharmadive.com ↗
02Why Muscle Cells Might Do Some Heavy Lifting

Brown was studying gene therapy in the 1990s when he designed a technology to turn mRNA expression on or off in different cells. For the new mouse study, published in Nature Biotechnology , he adapted the technology to turn off mRNA expression in dendritic cells, muscle cells, or liver cells. The researchers then vaccinated the mice with each version, delivering the vaccines both intravenously and intramuscularly. “The results were pretty stunning,” Brown said. When mRNA expression was turned off in muscle cells, T-cell response went down, suggesting muscle cells play a role in immunity. When expression was turned off in liver cells, T-cell expression tripled — indicating liver cells dampen immunity. Turning off expression in dendritic cells had no effect on T-cell activation, though it did reduce the number of killer T cells by as much as half. (Interestingly, no such reduction occurred when the antigen was SARS-CoV-2 spike. Brown is now investigating why different antigens had varying effects.) Knowing all this is crucial for designing effective mRNA vaccines and therapies. That’s because different mRNA therapies require different strategies. Cancer vaccines must boost tumor-fighting killer (CD8+) T cells. For genetic disease treatments, scientists want to avoid triggering the immune system to prevent killing the very cells the mRNA is meant to modify. “Understanding the immunology is extremely important for this class of drug,” Brown said. The finding doesn’t mean dendritic cells aren’t important for mRNA vaccines to work. “It just means that the mRNA doesn’t have to get into those cells to induce an immune response,” Brown said. Instead, the antigen can be transferred to those dendritic cells.

Source: www.medscape.com ↗
03Lifestyle Matters: How do environmental and lifestyle factors influence Alzheimer’s disease?

Dr. Harrison and Finnish neuroscientist Dr. Miia Kivipelto explore the complex interplay between genetics and lifestyle in Alzheimer's development. Learn how the groundbreaking FINGER study demonstrates potential prevention strategies, and discover the latest evidence on how environmental factors, diet, and chronic conditions influence Alzheimer's risk.

Source: www.biopharmadive.com ↗
04What the Artificial Neuron Cannot Do

Hersam’s next goal is a small circuit — perhaps 10 artificial neurons — where each one fires differently, and together they accomplish what would require thousands of conventional transistors. “ Silicon achieves complexity by having billions of identical devices,” Hersam said. “The brain is the opposite. It’s heterogeneous. The complexity is at the device level.” But Gaudet sees a gap no circuit design can yet fill: Biological neurons grow new connections and prune old ones, strengthening pathways that are used and weakening those that aren’t. Hersam’s lab’s printed neurons — or any other neuromorphic technology that mimics neuronal dynamics — can’t achieve that level of complexity yet. Brown is careful about the distance remaining between these printed neurons and the real thing. “Neurons are just so flexible,” he said. “They can totally change what they’re doing based on whether they’ve learned something and based on your emotional state. There’s a lot of hidden mysteries.” Sangwan suspects the device has more to reveal. “It’s a nonlinear dynamical system,” he said. “We don’t fully know how many different variables you need to explain it. It’s just the beginning.” Hersam, Sangwan, Brown, Holla, and Gaudet reported having no relevant financial disclosures. Disclosure information for study authors is available in the original study publication.

Source: www.medscape.com ↗
05China: Threat or opportunity?

One of the biggest biotech news stories of recent years is China’s continued rise as a biotech and life sciences powerhouse. China conducts a quarter of all clinical trials and drug development and has almost 1,500 new drugs in development.¹ Many China-based biotechs have benefitted from government funds, out-licencing deals with large pharmas and venture capital funding. However, policymakers in the US and EU have concerns about the possible threat to their region’s biosecurity and competitiveness as centres for health and life science research. Given China’s increased importance, ICON Biotech conducted the same biotech sector survey with 100 China-based biotech leaders. The results show that Chinese biotechs face many of the same challenges as biotechs located elsewhere. They share the same funding challenges and burdens associated with increasingly complex clinical trials and regulations.

Source: www.biopharmadive.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →